26Oct 2024
Anlotinib with WBRT Shows Promise in Treating NSCLC Brain Metastases

Anlotinib with WBRT Shows Promise in Treating NSCLC Brain Metastases

The phase II prospective study assessed the efficacy and safety of whole brain radiotherapy (WBRT) combined with anlotinib in patients with advanced non-small cell lung cancer (NSCLC) and multiple brain metastases (BMs). Twenty-eight patients were treated with anlotinib (8–12 mg) during a 21-day cycle alongside WBRT (30 Gy/12 F) and maintenance anlotinib until disease progression. Key outcomes included intracranial progression-free survival (iPFS), intracranial objective response rate (iORR), and overall survival (OS). Results revealed a median iPFS of 11.1 months and median OS of 13.4 months, with a 71.4% iORR. Common adverse events included hypertension (71.4%), fatigue (64.3%), and anorexia (46.4%). Findings suggest that anlotinib combined with WBRT offers effective, well-tolerated treatment for NSCLC with BMs.

  • #neurology

Like

Save

Share